April 07, 2020 + Jessica Di Palo
3 Min read
MTIP welcomes in April Christoph Mårtensson as Investment Associate and Jessica Di Palo as Head of Marketing and Communications!
In the midst of the Covid-19 crisis, the healthcare industry is experiencing an unprecedented boom. We at MTIP are also currently experiencing a peak, as we had the honour of welcoming two new employees in April. One is Christoph Mårtensson, who is starting as an Investment Associate, and the other is Jessica Di Palo, who will take on the new role as Head of Marketing and Communications.
Christoph Mårtensson has a scientific background in biochemistry and molecular biology. He received his Ph.D. with distinction from the University of Freiburg, Germany. During his academic years, he published several research projects in high-impact journals such as Nature and Cell. He studied Molecular Life Science at the University of Lübeck and spent a semester abroad at Imperial College London. His studies will allow him a very distinctive point of view on his day to day work, especially in evaluating interesting investment opportunities.
While studying communications at the University of Zurich, Jessica Di Palo began her career at the advertising agency TBWA\Switzerland. During her master’s degree she gained a lot of experience in marketing and sales at Basler Versicherungen AG. After her graduation she learned everything about digital marketing at the digital agency Mind Studios from where she switched again to marketing at UVEX Arbeitsschutz (Schweiz) AG. With a passion for marketing and communication, she joins MTIP to work with its world class international team to amplify their vision to create true long-term value in key markets around the world.
MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments
MTIP Fund II is closed!
Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics
Cynerio's new product Cynerio Now!
MTIP invests in Mediktor
New investment in Mediktor
SFDR Art. 8 or Art. 9? What’s the difference?
SFDR: getting the terminology right
MTIP participates in Oviva’s new $80m Series C funding
Oviva raises $80 million financing round
MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence
MTIP's new investment in Intelligencia
Private Equity 101: Part one – Glossary
Are you new to the healthtech space?
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper
Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch
Elite Summit 2019
MTIP Healthcare Clinic 2019
Healthcare clinic 2019
New MTIP investment in Cynerio
New investment in Cynerio